{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:07:57Z","timestamp":1785496077948,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T00:00:00Z","timestamp":1516060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T00:00:00Z","timestamp":1516060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr &amp; Diabetes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\/Objectives<\/jats:title>\n                <jats:p>Prolactin-releasing peptide (PrRP) has a potential to decrease food intake and ameliorate obesity, but is ineffective after peripheral administration. We have previously shown that our novel lipidized analogs PrRP enhances its stability in the circulation and enables its central effect after peripheral application. The purpose of this study was to explore if sub-chronic administration of novel PrRP analog palmitoylated in position 11 (palm<jats:sup>11<\/jats:sup>-PrRP31) to Koletsky-spontaneously hypertensive obese rats (SHROB) could lower body weight and glucose intolerance as well as other metabolic parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Subjects\/Methods<\/jats:title>\n                <jats:p>The SHROB rats (<jats:italic>n<\/jats:italic>\u2009=\u200916) were used for this study and age-matched hypertensive lean SHR littermates (<jats:italic>n<\/jats:italic>\u2009=\u200916) served as controls. Palm<jats:sup>11<\/jats:sup>-PrRP31 was administered intraperitoneally to SHR and SHROB (<jats:italic>n<\/jats:italic>\u2009=\u20098) at a dose of 5\u2009mg\/kg once-daily for 3 weeks. During the dosing period food intake and body weight were monitored. At the end of the experiment the oral glucose tolerance test was performed; plasma and tissue samples were collected. Thereafter, arterial blood pressure was measured.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At the end of the experiment, vehicle-treated SHROB rats showed typical metabolic syndrome parameters, including obesity, glucose intolerance, dyslipidemia, and hypertension. Peripheral treatment with palm<jats:sup>11<\/jats:sup>-PrRP31 progressively decreased the body weight of SHR rats but not SHROB rats, though glucose tolerance was markedly improved in both strains. Moreover, in SHROB palm<jats:sup>11<\/jats:sup>-PrRP31 ameliorated the HOMA index, insulin\/glucagon ratio, and increased insulin receptor substrate 1 and 2 expression in fat and insulin signaling in the hypothalamus, while it had no effect on blood pressure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We demonstrated that our new lipidized PrRP analog is capable of improving glucose tolerance in obese SHROB rats after peripheral application, suggesting that its effect on glucose metabolism is independent of leptin signaling and body weight lowering. These data suggest that this analog has the potential to be a compound with both anti-obesity and glucose-lowering properties.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41387-017-0015-8","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T11:03:32Z","timestamp":1515582212000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study"],"prefix":"10.1038","volume":"8","author":[{"given":"Barbora","family":"Mikul\u00e1\u0161kov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Holubov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Pra\u017eienkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Zemenov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Hrub\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Haluz\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanka","family":"\u017delezn\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Kune\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Malet\u00ednsk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,16]]},"reference":[{"key":"15_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.npep.2011.03.001","volume":"45","author":"L Malavolta","year":"2011","unstructured":"Malavolta, L. & Cabral, F. R. Peptides: important tools for the treatment of central nervous system disorders. Neuropeptides 45, 309\u2013316 (2011).","journal-title":"Neuropeptides"},{"key":"15_CR2","doi-asserted-by":"publisher","first-page":"R51","DOI":"10.1530\/JOE-16-0046","volume":"230","author":"J Kune\u0161","year":"2016","unstructured":"Kune\u0161, J. et al. Prolactin-releasing peptide: a new tool for obesity treatment. J. Endocrinol. 230, R51\u2013R58 (2016).","journal-title":"J. Endocrinol."},{"key":"15_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1042\/CS20110006","volume":"121","author":"VA Gault","year":"2011","unstructured":"Gault, V. A., Kerr, B. D., Harriott, P. & Flatt, P. R. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with type 2 diabetes and obesity. Clin. Sci. (Lond.) 121, 107\u2013117 (2011).","journal-title":"Clin. Sci. (Lond.)"},{"key":"15_CR4","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau, J. et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J. Med. Chem. 58, 7370\u20137380 (2015).","journal-title":"J. Med. Chem."},{"key":"15_CR5","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1023\/B:PHAM.0000036926.54824.37","volume":"21","author":"S Havelund","year":"2004","unstructured":"Havelund, S. et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm. Res. 21, 1498\u20131504 (2004).","journal-title":"Pharm. Res."},{"key":"15_CR6","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/ijo.2015.28","volume":"39","author":"L Maletinska","year":"2015","unstructured":"Maletinska, L. et al. Novel lipidized analogs of prolactin-releasing peptide have prolonged half-lives and exert anti-obesity effects after peripheral administration. Int. J. Obes. (Lond.) 39, 986\u2013993 (2015).","journal-title":"Int. J. Obes. (Lond.)"},{"key":"15_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.peptides.2015.11.005","volume":"75","author":"B Mikulaskova","year":"2016","unstructured":"Mikulaskova, B. et al. Effect of palmitoylated prolactin-releasing peptide on food intake and neural activation after different routes of peripheral administration in rats. Peptides 75, 109\u2013117 (2016).","journal-title":"Peptides"},{"key":"15_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1530\/JOE-15-0519","volume":"229","author":"M Holubova","year":"2016","unstructured":"Holubova, M. et al. Palmitoylated PrRP analog decreases body weight in DIO rats but not in ZDF rats. J. Endocrinol. 229, 85\u201396 (2016).","journal-title":"J. Endocrinol."},{"key":"15_CR9","first-page":"121","volume":"67","author":"V Prazienkova","year":"2016","unstructured":"Prazienkova, V. et al. Pharmacological characterization of lipidized analogs of prolactin-releasing peptide with a modified C-terminal aromatic ring. J. Physiol. Pharmacol. 67, 121\u2013128 (2016).","journal-title":"J. Physiol. Pharmacol."},{"key":"15_CR10","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1093\/jn\/128.12.2299","volume":"128","author":"T Ishizuka","year":"1998","unstructured":"Ishizuka, T. et al. Phenotypic consequences of a nonsense mutation in the leptin receptor gene (fak) in obese spontaneously hypertensive Koletsky rats (SHROB). J. Nutr. 128, 2299\u20132306 (1998).","journal-title":"J. Nutr."},{"key":"15_CR11","doi-asserted-by":"crossref","unstructured":"Pra\u017eienkov\u00e1, V. et al. Impact of novel palmitoylated prolactin-releasing peptide analogs on metabolic changes in mice with diet-induced obesity. PLoS ONE (2017) (in press).","DOI":"10.1371\/journal.pone.0183449"},{"key":"15_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0014-4800(73)90040-3","volume":"19","author":"S Koletsky","year":"1973","unstructured":"Koletsky, S. Obese spontaneously hypertensive rats\u2014a model for study of atherosclerosis. Exp. Mol. Pathol. 19, 53\u201360 (1973).","journal-title":"Exp. Mol. Pathol."},{"key":"15_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jnutbio.2007.05.001","volume":"19","author":"C Xu","year":"2008","unstructured":"Xu, C. et al. Metabolic dysregulation in the SHROB rat reflects abnormal expression of transcription factors and enzymes that regulate carbohydrate metabolism. J. Nutr. Biochem. 19, 305\u2013312 (2008).","journal-title":"J. Nutr. Biochem."},{"key":"15_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ng1096-130","volume":"14","author":"K Takaya","year":"1996","unstructured":"Takaya, K. et al. Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat. Genet. 14, 130\u2013131 (1996).","journal-title":"Nat. Genet."},{"key":"15_CR15","first-page":"E1014","volume":"273","author":"JE Friedman","year":"1997","unstructured":"Friedman, J. E. et al. Reduced insulin receptor signaling in the obese spontaneously hypertensive Koletsky rat. Am. J. Physiol. 273, E1014\u2013E1023 (1997).","journal-title":"Am. J. Physiol."},{"key":"15_CR16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3233\/JAD-143150","volume":"45","author":"A Spolcova","year":"2015","unstructured":"Spolcova, A. et al. Anorexigenic lipopeptides ameliorate central insulin signaling and attenuate tau phosphorylation in hippocampi of mice with monosodium glutamate-induced obesity. J. Alzheimers Dis. 45, 823\u2013835 (2015).","journal-title":"J. Alzheimers Dis."},{"issue":"Suppl 2","key":"15_CR17","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.33549\/physiolres.932394","volume":"61","author":"Z Pap\u00e1\u010dkov\u00e1","year":"2012","unstructured":"Pap\u00e1\u010dkov\u00e1, Z., Da\u0148kov\u00e1, H., P\u00e1len\u00ed\u010dkov\u00e1, E., Kazdov\u00e1, L. & Cahov\u00e1, M. Effect of short- and long-term high-fat feeding on autophagy flux and lysosomal activity in rat liver. Physiol. Res. 61(Suppl 2), S67\u2013S76 (2012).","journal-title":"Physiol. Res."},{"key":"15_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0895-7061(00)01229-2","volume":"14","author":"MC Lansang","year":"2001","unstructured":"Lansang, M. C., Williams, G. H. & Carroll, J. S. Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension. Am. J. Hypertens. 14, 51\u201353 (2001).","journal-title":"Am. J. Hypertens."},{"key":"15_CR19","doi-asserted-by":"publisher","first-page":"S254","DOI":"10.1111\/j.1440-1681.1995.tb02905.x","volume":"22","author":"RJ Koletsky","year":"1995","unstructured":"Koletsky, R. J., Boccia, J. & Ernsberger, P. Acceleration of renal disease in obese SHR by exacerbation of hypertension. Clin. Exp. Pharmacol. Physiol. Suppl. 22, S254\u2013S256 (1995).","journal-title":"Clin. Exp. Pharmacol. Physiol. Suppl."},{"key":"15_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1258\/ebm.2010.010161","volume":"236","author":"B Chen","year":"2011","unstructured":"Chen, B. et al. Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats. Exp. Biol. Med. (Maywood) 236, 309\u2013314 (2011).","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"15_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/153537020222700303","volume":"227","author":"RA Velliquette","year":"2002","unstructured":"Velliquette, R. A., Koletsky, R. J. & Ernsberger, P. Plasma glucagon and free fatty acid responses to a glucose load in the obese spontaneous hypertensive rat (SHROB) model of metabolic syndrome X. Exp. Biol. Med. (Maywood) 227, 164\u2013170 (2002).","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"15_CR22","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/j.peptides.2005.05.027","volume":"26","author":"E Keen-Rhinehart","year":"2005","unstructured":"Keen-Rhinehart, E., Kalra, S. P. & Kalra, P. S. AAV-mediated leptin receptor installation improves energy balance and the reproductive status of obese female Koletsky rats. Peptides 26, 2567\u20132578 (2005).","journal-title":"Peptides"},{"key":"15_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.regpep.2003.12.016","volume":"119","author":"E Keen Rhinehart","year":"2004","unstructured":"Keen Rhinehart, E., Kalra, S. P. & Kalra, P. S. Neuropeptidergic characterization of the leptin receptor mutated obese Koletsky rat. Regul. Pept. 119, 3\u201310 (2004).","journal-title":"Regul. Pept."},{"key":"15_CR24","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","volume":"65","author":"A Montagner","year":"2016","unstructured":"Montagner, A. et al. Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut 65, 1202\u20131214 (2016).","journal-title":"Gut"},{"key":"15_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1073\/pnas.1423952112","volume":"112","author":"DF Vatner","year":"2015","unstructured":"Vatner, D. F. et al. Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids. Proc. Natl. Acad. Sci. USA 112, 1143\u20131148 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"15_CR26","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.peptides.2010.12.011","volume":"32","author":"J Maixnerov\u00e1","year":"2011","unstructured":"Maixnerov\u00e1, J. et al. Characterization of prolactin-releasing peptide: binding, signaling and hormone secretion in rodent pituitary cell lines endogenously expressing its receptor. Peptides 32, 811\u2013817 (2011).","journal-title":"Peptides"},{"key":"15_CR27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fendo.2016.00138","volume":"7","author":"M Thon","year":"2016","unstructured":"Thon, M., Hosoi, T. & Ozawa, K. Possible integrative actions of leptin and insulin signaling in the hypothalamus targeting energy homeostasis. Front Endocrinol. (Lausanne) 7, 138 (2016).","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"15_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1210\/endo.143.1.8586","volume":"143","author":"J Hayakawa","year":"2002","unstructured":"Hayakawa, J. et al. Regulation of the PRL promoter by Akt through cAMP response element binding protein. Endocrinology 143, 13\u201322 (2002).","journal-title":"Endocrinology"},{"key":"15_CR29","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1210\/en.2009-0445","volume":"150","author":"J German","year":"2009","unstructured":"German, J. et al. Hypothalamic leptin signaling regulates hepatic insulin sensitivity via a neurocircuit involving the vagus nerve. Endocrinology 150, 4502\u20134511 (2009).","journal-title":"Endocrinology"},{"key":"15_CR30","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.amjhyper.2007.02.015","volume":"20","author":"P Ernsberger","year":"2007","unstructured":"Ernsberger, P., Johnson, J. L., Rosenthal, T., Mirelman, D. & Koletsky, R. J. Therapeutic actions of allylmercaptocaptopril and captopril in a rat model of metabolic syndrome. Am. J. Hypertens. 20, 866\u2013874 (2007).","journal-title":"Am. J. Hypertens."},{"key":"15_CR31","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/j.1476-5381.2010.00835.x","volume":"160","author":"X Rong","year":"2010","unstructured":"Rong, X. et al. Irbesartan treatment up-regulates hepatic expression of PPARalpha and its target genes in obese Koletsky (fa(k)\/fa(k)) rats: a link to amelioration of hypertriglyceridaemia. Br. J. Pharmacol. 160, 1796\u20131807 (2010).","journal-title":"Br. J. Pharmacol."},{"key":"15_CR32","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/j.1463-1326.2011.01471.x","volume":"13","author":"M Zhao","year":"2011","unstructured":"Zhao, M. et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes. Metab. 13, 1123\u20131129 (2011).","journal-title":"Diabetes Obes. Metab."},{"key":"15_CR33","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1124\/jpet.104.080606","volume":"314","author":"RA Velliquette","year":"2005","unstructured":"Velliquette, R. A., Friedman, J. E., Shao, J., Zhang, B. B. & Ernsberger, P. Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X. J. Pharmacol. Exp. Ther. 314, 422\u2013430 (2005).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"15_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri2921","volume":"11","author":"N Ouchi","year":"2011","unstructured":"Ouchi, N., Parker, J. L., Lugus, J. J. & Walsh, K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11, 85\u201397 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"15_CR35","first-page":"19","volume":"74","author":"N Ouchi","year":"2012","unstructured":"Ouchi, N., Ohashi, K., Shibata, R. & Murohara, T. Adipocytokines and obesity-linked disorders. Nagoya J. Med. Sci. 74, 19\u201330 (2012).","journal-title":"Nagoya J. Med. Sci."},{"key":"15_CR36","first-page":"531","volume":"7","author":"X Wang","year":"2014","unstructured":"Wang, X. et al. Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals. Diabetes Metab. Syndr. Obes. 7, 531\u2013541 (2014).","journal-title":"Diabetes Metab. Syndr. Obes."}],"container-title":["Nutrition &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41387-017-0015-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41387-017-0015-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41387-017-0015-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T16:06:40Z","timestamp":1671725200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41387-017-0015-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,16]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["15"],"URL":"https:\/\/doi.org\/10.1038\/s41387-017-0015-8","relation":{},"ISSN":["2044-4052"],"issn-type":[{"value":"2044-4052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,16]]},"assertion":[{"value":"23 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s note"}}],"article-number":"5"}}